Clinical Trials on Leukemia, B-Cell

Total 38365 results

National Cancer Institute (NCI)

Enrolling by invitation

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

Lymphoma | Leukemia | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Diffuse Large B Cell Lymphoma

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Lymphoma, B-Cell, Marginal Zone | Leukemia, Lymphoid | Leukemia, Lymphocytic, Chronic, B-Cell

China
Institute of Hematology & Blood Diseases Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...

Unknown

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma | Peripheral T Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma | Chronic Lymphoblastic Leukemia

China
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
TCR2 Therapeutics

Completed

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.

Withdrawn

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | CLL/SLL | SLL

United States
Asan Medical Center

Terminated

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Lymphoblastic Lymphoma | Leukemia, Biphenotypic, Acute | Leukemia, Acute Lymphoblastic | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Precursor B-Cell Lymphoblastic Leukemia

Korea, Republic of
Mela Osorio Maria Jose
Janssen-Cilag Ltd.

Completed

A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia

CLL

Argentina
Chronic Lymphocytic Leukemia Research Consortium
Celgene Corporation

Unknown

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | CLL | Untreated | First-Line | Front-line | Initial Therapy

United States
Tampere University Hospital

Completed

Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) (KLL3)

CLL

Finland
University of California, Irvine
United States Department of Defense

Active, not recruiting

Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, Refractory

United States
Ohio State University Comprehensive Cancer Center
Astex Pharmaceuticals, Inc.

Completed

Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

B-Chronic Lymphocytic Leukemia

United States
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
University of Arizona

Withdrawn

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (S-BR)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Mediastinal Large B-cell Lymphoma | Grey Zone Lymphoma | High Grade B Cell Lymphoma

United States
AbbVie (prior sponsor, Abbott)

Completed

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | B-cell Chronic Lymphocytic Leukemia | Myelodysplasia

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Tandem Auto-Allo Transplant for Lymphoma

Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Lymphoma, Low-Grade | Diffuse, Large B-Cell, Lymphoma | T-Cell Lymphoma | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic

United States
M.D. Anderson Cancer Center
Sanofi

Completed

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Leukemia | Richter's Transformation

United States
Novartis Pharmaceuticals

Recruiting

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Diffuse Large B-cell Lymphoma

Brazil
National Institute on Aging (NIA)
National Cancer Institute (NCI)

Completed

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
920th Hospital of Joint Logistics Support Force...
Gracell Biotechnology Shanghai Co., Ltd.; Kunming Hope of Health Hospital

Recruiting

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B-cell Non-hodgkin Lymphoma

China
Seattle Children's Hospital

Active, not recruiting

A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

B Cell Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients (ENSIGN)

B-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
Mundipharma Research Limited
Innovative Therapies For Children with Cancer Consortium

Terminated

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777-108)

Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's Lymphoma

Czech Republic, Austria, France, Germany, Italy, United Kingdom
Memorial Sloan Kettering Cancer Center
Actinium Pharmaceuticals

Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, Nos

United States
Nanfang Hospital of Southern Medical University

Recruiting

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Leukemia | Leukemia, B-cell | Leukemia, Acute | Leukemia, Lymphoblastic

China
Beijing Immunochina Medical Science & Technology...
Peking University People's Hospital

Not yet recruiting

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

Leukemia, B-cell
KK Women's and Children's Hospital
Singapore General Hospital

Recruiting

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | B-cell Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

Singapore
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
Poseida Therapeutics, Inc.
Roche-Genentech

Recruiting

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | CD20 Positive | T-Cell Non-Hodgkin Lymphoma

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
CytoCares Inc

Recruiting

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non-hodgkin Lymphoma | Acute Lymphoblastic Leukaemia

China
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Follicular Lymphoma | Marginal Zone Lymphoma | DLBCL | CLL | MCL | Indolent Lymphoma | Richter's Transformation | SLL | Mediastinal Large B-cell Lymphoma | Aggressive Lymphoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Celgene Corporation

Terminated

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia

United States
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

Leukemia, B-cell

China
University of Milano Bicocca

Recruiting

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.

Mantle-cell Lymphoma | B Cell Chronic Lymphocytic Leukemia

Italy
IDP Discovery Pharma S.L.

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Chronic Lymphocytic Leukemia (CLL) | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Multiple Myeloma (MM) | High Grade B-Cell Lymphoma, Not Otherwise Specified | Double Hit Lymphoma | Triple Hit Lymphoma

Spain
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First Affiliated Hospital of Soochow University

Unknown

γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse (γδT)

Leukemia, B-cell

China
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma | Leukemia

United States
Rong Tao
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia With Failed Remission

China
Massachusetts General Hospital
GlaxoSmithKline; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical...

Completed

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States
AstraZeneca

Recruiting

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Japan
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Follicular Lymphoma | Multiple Myeloma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Myelodysplasia | Acute Myeloid Leukemia... and other conditions

United States
Pharmacyclics LLC.
Ohio State University

Completed

Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL (PCYC-1109-CA)

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter's Transformation | Prolymphocyctic Leukemia

United States
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain

Clinical Trials on Leukemia, B-Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations